卵母细胞冷冻保存的结局:基于年龄和治疗指征的分析
该回顾性队列研究分析澳大利亚墨尔本一家IVF诊所2014年1月至2023年12月间3164名女性的4577个卵母细胞冷冻周期,主要结局为每复温周期的累积活产率。冷冻时年龄显著影响累积活产率,年轻患者成功率更高,而不同治疗指征间差异无统计学意义。
要点
- 冷冻时年龄<35岁者每启动复温周期的累积活产率最高(49.0%),35-40岁为36.8%,>40岁最低(17.2%)(P<0.01)。
- 癌症组卵母细胞复温存活率(81.5%)低于其他医学组(85.3%)和非医学组(83.3%)(P<0.01)。
- 癌症组累积活产率(35.6%)与其他医学组(36.0%)和非医学组(39.3%)的差异未达统计学显著(P>0.05)。
核心结论
- 冷冻时年龄显著影响每复温周期的累积活产率,年轻患者成功率更高,而不同治疗指征间的差异无统计学意义。
- 作者认为这些发现强化了在年龄可控时尽早进行卵母细胞冷冻以最大化生育力保存结局的重要性。
- 作者指出尽管癌症患者成功率略低,卵母细胞冷冻仍是这些个体的有价值选择。
研究设计与样本
- 回顾性队列研究,分析澳大利亚墨尔本一家IVF诊所2014年1月至2023年12月间3164名女性的4577个卵母细胞冷冻周期。
- 主要结局为每复温周期的累积活产率,次要结局包括冷冻卵母细胞数、复温存活率、受精率、优质胚胎发育、临床妊娠率和流产率。
- 数据来自电子临床记录,卵母细胞冷冻周期按取卵时年龄和治疗指征(癌症诊断、其他医学状况、非医学原因)分类。
主要发现
- 卵母细胞冷冻时平均年龄在癌症组最低(31.3±6.2岁),其他医学组为34.4±4.5岁,非医学组为36.2±3.1岁(P<0.01)。
- 研究期间共进行647个复温卵母细胞周期。
- 癌症组卵母细胞存活率(81.5%)低于其他医学组(85.3%)和非医学组(83.3%)(P<0.01)。
- 每启动复温周期的累积活产率在<35岁患者最高(49.0%),35-40岁次之(36.8%),>40岁最低(17.2%)(P<0.01)。
- 癌症组累积活产率(35.6%)与其他医学组(36.0%)和非医学组(39.3%)的差异未达统计学显著(P>0.05)。
临床怎么用
- 作者认为这些发现强化了在年龄可控时尽早进行卵母细胞冷冻以最大化生育力保存结局的重要性。
- 作者指出尽管癌症患者成功率略低,卵母细胞冷冻仍是这些个体的有价值选择。
- 作者提出需要进一步研究探讨特定癌症类型和治疗方案对卵母细胞质量和生殖结局的影响。
局限性
- 研究的回顾性设计是显著局限。
- 「其他医学」组中医学指征的异质性是显著局限。
- 作者提出需要进一步研究探讨特定癌症类型和治疗方案对卵母细胞质量和生殖结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How do age at oocyte cryopreservation (OC) and treatment indication affect the outcomes of OC cycles, particularly cumulative live birth rates (CLBR) per warm cycle? SUMMARY ANSWER: Age at OC significantly influenced CLBRs per warm cycle, with younger patients achieving higher success, while differences between treatment indications were not statistically significant. WHAT IS KNOWN ALREADY: OC is a well-established fertility preservation method, with success rates largely influenced by the woman's age at the time of freezing. However, limited data exist on how various medical and non-medical (elective) indications affect outcomes. STUDY DESIGN, SIZE, DURATION: This retrospective cohort study analyzed 4577 OC cycles from 3164 women treated between January 2014 and December 2023 at Melbourne IVF clinic, Australia. The primary outcome was CLBR per warm cycle. Secondary outcomes included the number of oocytes cryopreserved, oocyte survival rate upon warming, fertilization rate, good-quality embryo development, clinical pregnancy rate and miscarriage rate. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were obtained from electronic clinical records. OC cycles were categorized by age at oocyte retrieval and treatment indication: cancer diagnosis, other medical conditions and non-medical reasons. MAIN RESULTS AND THE ROLE OF CHANCE: The mean age at OC was lowest in the cancer group (31.3 ± 6.2 years) compared to other medical (34.4 ± 4.5 years) and non-medical (36.2 ± 3.1 years) groups (P < 0.01). During the study period, 647 warmed oocyte cycles were conducted. Oocyte survival rate was lower in the cancer group (81.5%) compared with other medical (85.3%) and non-medical (83.3%) groups (P < 0.01). The CLBR per started warm cycle was highest in patients under 35 years old (49.0%), followed by those aged 35-40 (36.8%) and lowest in patients over 40 (17.2%) (P < 0.01). Although CLBR appeared lower in the cancer group (35.6%) compared with other medical (36.0%) and non-medical (39.3%) groups, the differences did not reach statistical significance (P > 0.05). LIMITATIONS, REASONS FOR CAUTION: The study's retrospective design and the heterogeneity of medical indications in the "other medical" group are notable limitations. WIDER IMPLICATIONS OF THE FINDINGS: These findings reinforce the importance of early OC, when age is a controllable factor, to maximize fertility preservation outcomes. While cancer patients showed slightly lower success rates, OC remains a valuable option for these individuals. Further studies are needed to explore the impact of specific cancer types and treatment regimens on oocyte quality and reproductive outcomes. STUDY FUNDING/COMPETING INTEREST(S): No external funding was received for this study. The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Kirshenbaum M, Stern C, Wale P, et al. Outcomes of oocyte cryopreservation: an analysis based on age and treatment indications. Hum Reprod. 2025. PMID: 40796142. doi:10.1093/humrep/deaf147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。